SPHK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL19994	0.50	15/20
Sphingosine (SCHEMBL19398)	1.00	12/20
Sphingosine (SCHEMBL19399)	1.00	12/20
Sphingosine (SCHEMBL195874)	0.97	12/20
Sphingosine (SCHEMBL195875)	0.97	12/20
SCHEMBL177138	0.60	12/20
SCHEMBL29418	0.40	12/20
SCHEMBL120911	1.00	10/20
SCHEMBL94738	0.57	10/20
SCHEMBL94737	0.54	10/20
SCHEMBL95836	0.57	9/20
SCHEMBL95494	0.55	9/20
SCHEMBL95835	0.54	9/20
SCHEMBL94884	0.56	8/20
SCHEMBL96694	0.56	7/20
SCHEMBL50887	0.47	7/20
SCHEMBL51523	0.47	7/20
SCHEMBL52008	0.47	7/20
SCHEMBL52034	0.47	7/20
SCHEMBL93394	0.47	7/20

Clinical trials — most relevant to SPHK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study	PHASE4	COMPLETED
A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis	PHASE4	WITHDRAWN
Sphingosine-1-phosphate and Pneumonia	PHASE2/PHASE3	UNKNOWN
Repurposing Siponimod for Alzheimer's Disease	PHASE2	RECRUITING
Fingolimod in Schizophrenia Patients	PHASE2	COMPLETED
Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma	PHASE1/PHASE2	WITHDRAWN
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula	PHASE2	COMPLETED
Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer	PHASE2	NOT_YET_RECRUITING
Efficacy and Safety of FTY720 for Acute Stroke	PHASE2	COMPLETED
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.	PHASE1	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Identification of Biomarkers and Molecular Targets Involved on Intervertebral Disc Degeneration and Discogenic Pain	nan	UNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure	nan	COMPLETED
Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis	nan	UNKNOWN
Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma	nan	SUSPENDED
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma	nan	RECRUITING
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes	nan	COMPLETED
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study	nan	UNKNOWN
Effect of Plasma Ceramides on Peripheral Vascular Function	nan	COMPLETED
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS)	nan	COMPLETED
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness	nan	UNKNOWN
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans	nan	COMPLETED
Ceramide Level as Apredictor of Outcomes in Patients of Anterior Myocardial Infarction Undergoing Primary Coronary Intervention	nan	UNKNOWN
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
The Role of Arachidonic Acid Metabolites, From Patients With Metabolic Syndrome	nan	UNKNOWN
Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720)	nan	UNKNOWN
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Extracellular Vesicles, Insulin Action, and Exercise	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SPHK1 binder may also engage these)

Protein	Name	Similarity
Q8CI15	—	0.998	Q8CI15 →
Q91V26	—	0.994	Q91V26 →
Q86U10	—	0.975	Q86U10 →
Q8R123	—	0.973	Q8R123 →
A0JNU3	—	0.973	A0JNU3 →
P51839	—	0.971	P51839 →
P51840	—	0.971	P51840 →
P55203	—	0.970	P55203 →
D3ZEY4	—	0.970	D3ZEY4 →
Q9ESK3	—	0.969	Q9ESK3 →
TARS2	Threonine--tRNA ligase, mitochondrial	0.969	landscape →
Q6P5E8	—	0.969	Q6P5E8 →
O43542	—	0.968	O43542 →
Q5RCH4	—	0.968	Q5RCH4 →
Q9HC96	—	0.968	Q9HC96 →
P52785	—	0.968	P52785 →
FLAD1	FAD synthase	0.968	landscape →
O88202	—	0.968	O88202 →
Q08DH8	—	0.967	Q08DH8 →
Q8VCZ9	—	0.967	Q8VCZ9 →
A0A1U8CC89	—	0.967	A0A1U8CC89 →
Q5JTZ9	—	0.967	Q5JTZ9 →
Q8HY87	—	0.967	Q8HY87 →
Q2V057	—	0.967	Q2V057 →
Q96MM6	—	0.967	Q96MM6 →
Q865R1	—	0.967	Q865R1 →
Q9H2F3	—	0.966	Q9H2F3 →
Q6MG21	—	0.966	Q6MG21 →
P52824	—	0.966	P52824 →
Q8BJ64	—	0.966	Q8BJ64 →